A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Eli Lilly and Company
ALX Oncology Inc.
National Institutes of Health Clinical Center (CC)
Pfizer
Aurigene Discovery Technologies Limited
Aurigene Discovery Technologies Limited
Pheon Therapeutics
Eli Lilly and Company
University of Pittsburgh
Kestrel Therapeutics, Inc.
National Cancer Institute (NCI)
Travera Inc
Revolution Medicines, Inc.
National Institutes of Health Clinical Center (CC)
Memorial Sloan Kettering Cancer Center
Seagen Inc.
Turning Point Therapeutics, Inc.
Alterome Therapeutics, Inc.
Avera McKennan Hospital & University Health Center
Orano Med LLC
RasCal Therapeutics, Inc.
Pfizer
Fondazione del Piemonte per l'Oncologia
Xencor, Inc.
City of Hope Medical Center
University Hospital, Clermont-Ferrand
University of Pennsylvania
Duke University
Washington University School of Medicine
A2 Biotherapeutics Inc.
Mirati Therapeutics Inc.
Arvinas Inc.
Zhejiang University
National Institutes of Health Clinical Center (CC)
MBrace Therapeutics
Ulsan University Hospital
New Phase Ltd.
Revolution Medicines, Inc.
University of Colorado, Denver
Roswell Park Cancer Institute
Pheon Therapeutics
City of Hope Medical Center
University of Nebraska
EXoPERT
Eli Lilly and Company
Novartis
Var2 Pharmaceuticals
University of Salamanca
National Institutes of Health Clinical Center (CC)
Centre Hospitalier Universitaire de Besancon